Market Summary
USD7.45-0.13
Market Closed-1.72%
BHC Stock Price
BHC RSI Chart
BHC Valuation
BHC Price/Sales (Trailing)
BHC Profitability
BHC Fundamentals
BHC Revenue
BHC Earnings
Price Action
52 Week Range
4.0023.97
(Low)(High)
Last 7 days
-4.4%
Last 30 days
-15.9%
Last 90 days
17.7%
Trailing 12 Months
-68.4%
BHC Financial Health
BHC Investor Care
Peers (Alternatives to Bausch Health Companies)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
JNJ | 396.9B | 94.9B | -4.42% | -11.67% | 22.12 | 4.18 | 1.25% | -14.07% |
LLY | 298.8B | 28.5B | 1.30% | 17.85% | 47.85 | 10.47 | 0.79% | 11.88% |
MRK | 272.8B | 59.3B | -5.09% | 32.83% | 17.88 | 4.63 | 21.72% | 11.27% |
PFE | 226.2B | 100.3B | -5.50% | -20.78% | 7.21 | 2.25 | 23.43% | 42.74% |
BMY | 142.4B | 46.2B | -5.97% | -4.10% | 22.5 | 3.08 | -0.49% | -9.54% |
| MID-CAP | ||||||||
PRGO | 4.5B | 4.5B | -8.55% | -11.11% | -32.05 | 1.01 | 7.56% | -104.06% |
RETA | 3.2B | 2.2M | 109.33% | 133.59% | -10.15 | 1.4K | -80.71% | -4.88% |
| SMALL-CAP | ||||||||
SUPN | 1.9B | 667.2M | -10.48% | 10.28% | 30.48 | 2.77 | 15.09% | 13.64% |
TLRY | 1.6B | 602.5M | -5.76% | -54.20% | -2.78 | 2.67 | 18.18% | -18.59% |
CGC | 923.6M | 478.9M | -20.83% | -73.20% | -0.29 | 1.93 | -31.50% | -634.70% |
INVA | 772.8M | 285.2M | -9.04% | -42.36% | 3.51 | 2.71 | -27.21% | -40.28% |
CRON | 726.9M | 114.5M | -12.79% | -47.96% | -4.31 | 6.35 | 27.90% | 57.40% |
ACRS | 539.5M | 29.8M | -36.94% | -53.16% | -6.21 | 18.13 | 340.05% | 4.35% |
OCUL | 379.1M | 51.5M | -14.46% | -5.94% | -5.34 | 7.36 | 18.32% | -984.05% |
ENDP | 94.1M | 2.3B | -43.99% | -88.43% | -0.03 | 0.04 | -22.53% | -376.66% |
Financials for Bausch Health Companies
| Income Statement (Last 12 Months) | ||||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Revenue | 0.0% | 8,124,000,000 | 8,127,000,000 | 8,192,000,000 | 8,325,000,000 | 8,434,000,000 |
| S&GA Expenses | -0.5% | 2,625,000,000 | 2,639,000,000 | 2,631,000,000 | 2,640,000,000 | 2,624,000,000 |
| EBITDA | -13.3% | 2,729,000,000 | 3,146,000,000 | 2,936,000,000 | 2,406,000,000 | - |
| EBITDA Margin | -13.2% | 0.34 | 0.39 | 0.36 | 0.29 | - |
| Earnings Before Taxes | -151.8% | -129,000,000 | 249,000,000 | 26,000,000 | -515,000,000 | -1,024,000,000 |
| EBT Margin | -151.8% | -0.02 | 0.03 | 0.00 | -0.06 | - |
| Interest Expenses | -2.4% | 1,464,000,000 | 1,500,000,000 | 1,466,000,000 | 1,420,000,000 | 1,426,000,000 |
| Net Income | -188.6% | -225,000,000 | 254,000,000 | 43,000,000 | -407,000,000 | -948,000,000 |
| Net Income Margin | -188.6% | -0.03 | 0.03 | 0.01 | -0.05 | - |
| Free Cahsflow | 32.9% | -946,000,000 | -1,409,000,000 | 409,000,000 | 671,000,000 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | -2.3% | 25,686 | 26,298 | 28,171 | 29,090 | 29,202 |
| Current Assets | 5.9% | 4,247 | 4,010 | 5,417 | 5,836 | 5,607 |
| Cash Equivalents | 16.0% | 564 | 486 | 659 | 1,249 | 582 |
| Inventory | 3.2% | 1,090 | 1,056 | 1,073 | 1,045 | 993 |
| Net PPE | 6.2% | 1,600 | 1,507 | 1,545 | 1,579 | 1,598 |
| Goodwill | -4.1% | 11,547 | 12,044 | 12,266 | 12,427 | 12,457 |
| Liabilities | -1.7% | 25,426 | 25,865 | 27,918 | 29,231 | 29,236 |
| Current Liabilities | 2.9% | 3,941 | 3,831 | 4,997 | 4,774 | 5,198 |
| Long Term Debt | -5.8% | 21,814 | 23,168 | 22,654 | - | - |
| LT Debt, Current | 5.1% | 432 | 411 | 150 | - | - |
| LT Debt, Non Current | -2.3% | 20,334 | 20,804 | 21,664 | 23,168 | 22,654 |
| Shareholder's Equity | 2.8% | 260 | 253 | -34.00 | - | - |
| Retained Earnings | -4.7% | -9,186 | -8,776 | -9,175 | -9,030 | -8,961 |
| Additional Paid-In Capital | 23.3% | 159 | 129 | 104 | 415 | 462 |
| Accumulated Depreciation | - | 1,820 | - | - | - | - |
| Shares Outstanding | 0.0% | 362 | 362 | 362 | 361 | 359 |
| Minority Interest | -0.6% | 952 | 958 | 946 | 75.00 | 72.00 |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | 38.3% | -728 | -1,179 | 648 | 920 | 1,426 |
| Share Based Compensation | 1.6% | 126 | 124 | 124 | 129 | 128 |
| Cashflow From Investing | -22.7% | -303 | -247 | 394 | 409 | 409 |
| Cashflow From Financing | -715.6% | -474 | 77.00 | -1,044 | -802 | -1,513 |
Risks for BHC
What is the probability of a big loss on BHC?
97.3%
Probability that Bausch Health Companies stock will be more than 20% underwater in next one year
72.7%
Probability that Bausch Health Companies stock will be more than 30% underwater in next one year.
36.9%
Probability that Bausch Health Companies stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does BHC drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Bausch Health Companies was unfortunately bought at previous high price.
Drawdowns
Returns for BHC
Cumulative Returns on BHC
-20.5%
10-Year Cumulative Returns
-18.5%
7-Year Cumulative Returns
-13.5%
5-Year Cumulative Returns
-17.5%
3-Year Cumulative Returns
What are the long-term rolling returns for BHC?
FIve years rolling returns for Bausch Health Companies.
Annualized Returns
Which funds bought or sold BHC recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-06 | Rockefeller Capital Management L.P. | unchanged | - | -4,000 | 41,000 | -% |
2023-02-27 | Parallax Volatility Advisers, L.P. | new | - | 2,905,620 | 2,905,620 | -% |
2023-02-24 | NATIXIS | added | 97.72 | 44,216,900 | 99,336,900 | 0.56% |
2023-02-21 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | reduced | -18.79 | -44,912 | 128,088 | -% |
2023-02-17 | TRUIST FINANCIAL CORP | reduced | -8.35 | -14,071 | 68,929 | -% |
2023-02-17 | Coppell Advisory Solutions Corp. | new | - | 1,256 | 1,256 | -% |
2023-02-16 | MAVERICK CAPITAL LTD | sold off | -100 | -278,000 | - | -% |
2023-02-15 | NOMURA HOLDINGS INC | reduced | -28.3 | -40,001,000 | 74,118,000 | 0.30% |
2023-02-15 | GABELLI & Co INVESTMENT ADVISERS, INC. | added | 20.67 | 10,668 | 113,668 | 0.02% |
2023-02-15 | BERKSHIRE ASSET MANAGEMENT LLC/PA | reduced | -9.24 | -14,176 | 67,824 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Bausch Health Companies News
Schedule 13G FIlings of Bausch Health Companies
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | nomura holdings inc | 3.6% | 13,030,352 | SC 13G/A | |
| Feb 13, 2023 | goldentree asset management lp | 5.4% | 19,421,054 | SC 13G | |
| May 13, 2022 | va partners i, llc | 4.0% | 14,430,901 | SC 13D/A | |
| Feb 14, 2022 | nomura holdings inc | 5.4% | 19,515,079 | SC 13G | |
| Dec 13, 2021 | glenview capital management, llc | 4.75% | 17,078,657 | SC 13D/A | |
| Jun 21, 2021 | va partners i, llc | 5.0% | 17,941,603 | SC 13D/A | |
| Apr 23, 2021 | meruelo alex | 5.51% | 19,604,777 | SC 13G | |
| Mar 16, 2021 | icahn carl c | 3.98% | 14,169,189 | SC 13D/A | |
| Mar 11, 2021 | icahn carl c | 3.98% | 14,169,189 | SC 13D/A | |
| Feb 24, 2021 | icahn carl c | - | 0 | SC 13D/A |
BHC Fair Value
Recent SEC filings of Bausch Health Companies
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Mar 07, 2023 | 4/A | Insider Trading | |
| Mar 06, 2023 | 144 | Notice of Insider Sale Intent | |
| Mar 06, 2023 | 4 | Insider Trading | |
| Mar 06, 2023 | 4 | Insider Trading | |
| Mar 06, 2023 | 4 | Insider Trading | |
| Mar 06, 2023 | 4 | Insider Trading | |
| Mar 01, 2023 | 4 | Insider Trading | |
| Mar 01, 2023 | 4 | Insider Trading | |
| Mar 01, 2023 | 8-K | Current Report | |
| Feb 23, 2023 | 8-K | Current Report |
Latest Insider Trading transactions for BHC
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-03-06 | Carson Seana | sold (taxes) | -4,539 | 9.17 | -495 | evp, general counsel |
2023-03-06 | Carson Seana | sold | -4,539 | 9.17 | -495 | evp, general counsel |
2023-03-03 | APPIO THOMAS | sold (taxes) | -93,203 | 9.16 | -10,175 | chief executive officer |
2023-03-03 | Carson Seana | sold | -7,285 | 9.34 | -780 | evp, general counsel |
2023-03-03 | Carson Seana | sold (taxes) | -42,093 | 9.19065 | -4,580 | evp, general counsel |
2023-03-02 | Vadaketh Tom George | sold (taxes) | -37,009 | 9.25 | -4,001 | evp, chief financial officer |
2023-03-02 | Vadaketh Tom George | acquired | - | - | 142,678 | evp, chief financial officer |
2023-03-02 | Carson Seana | acquired | - | - | 95,119 | evp, general counsel |
2023-03-02 | APPIO THOMAS | acquired | - | - | 523,155 | chief executive officer |
2023-03-02 | Carson Seana | sold (taxes) | -55,444 | 9.25 | -5,994 | evp, general counsel |
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
BHC Income Statement
2022-12-31CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Millions | 12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
| Revenues | |||
| Revenues | $ 8,124 | $ 8,434 | $ 8,027 |
| Expenses | |||
| Selling, general and administrative | 2,625 | 2,624 | 2,367 |
| Research and development | 529 | 465 | 452 |
| Amortization of intangible assets | 1,215 | 1,375 | 1,645 |
| Goodwill impairments | 824 | 469 | 0 |
| Asset impairments, including loss on assets held for sale | 15 | 234 | 114 |
| Restructuring, integration, separation and IPO costs | 63 | 50 | 22 |
| Other expense, net | 35 | 373 | 502 |
| Total Expenses | 7,670 | 7,984 | 7,351 |
| Operating income | 454 | 450 | 676 |
| Interest income | 14 | 7 | 13 |
| Interest expense | (1,464) | (1,426) | (1,534) |
| Gain (loss) on extinguishment of debt | 875 | (62) | (59) |
| Foreign exchange and other | (8) | 7 | (30) |
| Loss before income taxes | (129) | (1,024) | (934) |
| (Provision for) benefit from income taxes | (83) | 87 | 375 |
| Net loss | (212) | (937) | (559) |
| Net income attributable to noncontrolling interest | (13) | (11) | (1) |
| Net loss attributable to Bausch Health Companies Inc. | $ (225) | $ (948) | $ (560) |
| Basic loss per share attributable to Bausch Health Companies Inc. (in dollars per share) | $ (0.62) | $ (2.64) | $ (1.58) |
| Diluted loss per share attributable to Bausch Health Companies Inc. (in dollars per share) | $ (0.62) | $ (2.64) | $ (1.58) |
| Basic weighted-average common shares (in shares) | 362,000 | 358,900 | 355,000 |
| Diluted weighted-average common shares (in shares) | 362,000 | 358,900 | 355,000 |
| Product sales | |||
| Revenues | |||
| Revenues | $ 8,046 | $ 8,342 | $ 7,924 |
| Expenses | |||
| Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues | 2,336 | 2,361 | 2,202 |
| Other revenues | |||
| Revenues | |||
| Revenues | 78 | 92 | 103 |
| Expenses | |||
| Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues | $ 28 | $ 33 | $ 47 |
BHC Balance Sheet
2022-12-31CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 564 | $ 582 |
| Restricted cash and other settlement deposits | 27 | 1,537 |
| Trade receivables, net | 1,790 | 1,775 |
| Inventories, net | 1,090 | 993 |
| Prepaid expenses and other current assets | 776 | 720 |
| Total current assets | 4,247 | 5,607 |
| Property, plant and equipment, net | 1,600 | 1,598 |
| Intangible assets, net | 5,800 | 6,948 |
| Goodwill | 11,547 | 12,457 |
| Deferred tax assets, net | 2,166 | 2,252 |
| Other non-current assets | 326 | 340 |
| Total assets | 25,686 | 29,202 |
| Current liabilities: | ||
| Accounts payable | 521 | 407 |
| Accrued and other current liabilities | 2,988 | 4,791 |
| Current portion of long-term debt | 432 | 0 |
| Total current liabilities | 3,941 | 5,198 |
| Acquisition-related contingent consideration | 208 | 202 |
| Non-current portion of long-term debt | 20,334 | 22,654 |
| Deferred tax liabilities, net | 202 | 529 |
| Other non-current liabilities | 741 | 653 |
| Total liabilities | 25,426 | 29,236 |
| Commitments and contingencies (Notes 20 and 21) | ||
| Equity (Deficit) | ||
| Common shares, no par value, unlimited shares authorized, 361,898,846 and 359,405,748 issued and outstanding at December 31, 2022 and 2021, respectively | 10,391 | 10,317 |
| Additional paid-in capital | 159 | 462 |
| Accumulated deficit | (9,186) | (8,961) |
| Accumulated other comprehensive loss | (2,056) | (1,924) |
| Total Bausch Health Companies Inc. shareholders’ deficit | (692) | (106) |
| Noncontrolling interest | 952 | 72 |
| Total equity (deficit) | 260 | (34) |
| Total liabilities and equity (deficit) | $ 25,686 | $ 29,202 |